Sunday, June 5, 2011 | Oncolink

Oncolink Features

Find My Cancer Drug

Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial Presenter: Ruth Ladenstein, MD Presenter's Affiliation: St. Anna's Children Hospital; SIOPE (The European Society for Clinical Oncology) Background Neuroblastoma is a cancer of the sympathetic nervous system and is comprised of a ...
Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group Study AALL0232 Presenter: Eric C. Larsen, MD Presenter's Institution: Maine Children's Cancer Program, Scarborough, ME Background/Introduction There are approximately 5,300 new cases of acute lymphoblastic leukemia (ALL) diagnosed every year in the United...
Enzastaurin (ENZ) before and concomitant with radiation therapy (RTX) followed by ENZ maintenance therapy in patients with newly diagnosed glioblastoma (GBM) without hypermethylation of the O6-methylguanyl DNA-methyltransferase (MGMT) promoter: A multicenter, open-label, uncontrolled phase II study Presenter: Wolfgang Wick, MD Presenter's Institution: University Hospital Heidelberg, Heidelberg, Germany Background/Introduction The standard of care for patients diagnosed with Glioblastoma multiforme (GBM) includes maximal safe surgical...
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial) Presenter: V. Guarneri Presenter's Institution: Modena University Hospital, Modena, Italy Background The treatment of patients with breast cancer continues to evolve, with cytotoxic chemotherapy, endocrine therapy, and molecular targeted...
Outcome of infants and young children with newly diagnosed medulloblastoma treated on Head Start III protocol Presenter: Girish Dhall, MD Presenter's Affiliation: Children’s Hospital Los Angeles Background The standard of care for newly diagnosed medulloblastoma is tri-modality therapy with surgery, chemotherapy, and radiation all playing a role in...
Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma Presenter: Wolchok Presenter's Affiliation: Memorial Sloan Kettering Cancer Center, New York, NY Background Metastatic melanoma is an aggressive and deadly disease with limited treatment options. The incidence of metastatic...
Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma Presenter: P. B. Chapman Presenter's Institution: Memorial Sloan Kettering Cancer Center Background Dacarbazine (DTIC) was approved for melanoma in 1975; the overall response rate has been reported at 7-12% and median OS after starting the...
Prognostic factors for response and survival in primary central nervous system lymphoma (PCNSL) from a randomized phase III trial (G-PCNSL-SG-1) Presenter: K. Jahnke Presenter's Institution: Charité Hospital, Campus Benjamin Franklin, Berlin, Germany Background CNS lymphoma is rare but incidence is rising in both immunocompetent and imuunocompromised patients. For reference, the...
Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO) Presenter: Heikki Joensuu, MD Presenter's Institution: Helsinki University Central Hospital, Helsinki, Finland Background/Introduction Gastrointestinal stromal tumors (GISTs) are tumors of the bowel wall that originate in the...